Successful Treatment of an Adult Diffuse Midline Glioma With Olaparib Combined With Bevacizumab

Abstract

\n Diffuse midline gliomas (DMGs), characterized by malignant, fast growing and carrying a poor prognosis, are a rare subtype of glial tumor. Majority of DMGs harboring H3 K27-mutation are a novel entity with a worse prognosis and are categorized as a grade IV glioma. Histone-mutated DMGs characterized by a midline location occur more commonly in children and less frequently in adults. Considering the treatment is limited in DMG, the need for effective therapeutic strategies is urgent. Olaparib is one of Poly-ADP-Ribose Polymerase (PARP) inhibitors and has been reported in inhibiting glioma in some preclinical trials and clinical trial in glioblastoma. Olaparib plus bevacizumab have been successfully used in ovarian cancer. However, the olaparib application in DMGs has not been reported yet. Herein, we firstly reported that an adult DMG patient benefited from olaparib combined with bevacizumab. This report provides a promising treatment option for DMG patients.